58586-55-3

Usage

Uses

Used in Pharmaceutical Industry:
3-IODO-4-METHYL-BENZALDEHYDE is used as an intermediate in the manufacturing of pharmaceuticals for its ability to contribute to the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
3-IODO-4-METHYL-BENZALDEHYDE is used as a building block in the synthesis of agrochemicals, particularly for the development of pesticides and herbicides, due to its potential applications in enhancing crop protection.
Used in Organic Synthesis:
3-IODO-4-METHYL-BENZALDEHYDE is used as a reagent in the synthesis of other organic compounds, leveraging its chemical properties to facilitate reactions and form new molecules.
Used in Flavor and Fragrance Industry:
3-IODO-4-METHYL-BENZALDEHYDE is used as a component in the creation of flavors and perfumes, capitalizing on its aromatic properties to enhance the sensory qualities of these products.
Used in Dye and Pigment Industry:
3-IODO-4-METHYL-BENZALDEHYDE is used in the production of dyes and pigments, where its chemical structure contributes to the color and stability of these products.

InChI:InChI=1/C8H7IO/c1-6-2-3-7(5-10)4-8(6)9/h2-5H,1H3

Upstream product

• 52107-98-9 3-iodo-4-methylbenzoyl chloride 
• 104-87-0 4-methyl-benzaldehyde 
• 79-37-8 oxalyl dichloride 
• 82998-57-0 3-iodo-4-toluic acid 
• 165803-89-4 (3-iodo-4-methyl-phenyl)-methanol 

Downstream Products

• 675148-96-6 methyl 5-formyl-2-methylbenzoate 
• 372120-58-6 methyl 4-(3-iodo-4-methylphenyl)-2-methyl-5-oxo-4,5,6,8-tetrahydro-1H-pyrano[3,4-b]pyridine-3-carboxylate 
• 165803-90-7 3-iodo-4-methylstyrene 
• 1075177-08-0 2-iodo-1-methyl-4-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)benzene 
• 272130-87-7 methyl 5-(2-hydroxyethyl)-2-methylbenzoate 
• 272130-88-8 5-(2-bromo-ethyl)-2-methyl-benzoic acid methyl ester 
• 272130-84-4 methyl 2-methyl-5-vinylbenzoate 

Relevant academic research and scientific papers

Preparation and application of triazole compound

The invention provides preparation and application of a triazole compound. A preparation method comprises the following steps: enabling a first compound, namely 1-methyl-4-nitryl-2-(trifluoromethyl) benzene to react under the action of NBS, BPO and CCl4 s

N-Iodosuccinimide (NIS) in Direct Aromatic Iodination

N-Iodosuccinimide (NIS) in pure trifluoroacetic acid (TFA) offers a time-efficient and general method for the iodination of a wide range of mono- and disubstituted benzenes at room temperature, as demonstrated in this paper. The starting materials were generally converted into mono-iodinated products in less than 16 hours at room temperature, without byproducts. A few deactivated substrates needed addition of sulfuric acid to increase the reaction rate. Another exception was methoxybenzenes that preferentially were iodinated by NIS in acetonitrile with only catalytic amounts of TFA.

5-HT7receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity

5-HT7receptor (5-HT7R) agonists and antagonists have been reported to be used for treatment of neuropathic pain and depression, respectively. In this study, as a novel scaffold for 5-HT7R modulators, we designed and prepared a series of biphenyl-3-yl-methanamine derivatives with various amino groups. Evaluation of functional activities as well as binding affinities of the title compounds identified partial agonists (EC50?=?0.55–3.2?μM) and full antagonists (IC50?=?5.57–23.1?μM) depending on the amino substituents. Molecular docking study suggested that the ligand-based switch in functional activity from agonist to antagonist results from the size of the amino groups and thereby different binding modes to 5-HT7R. In particular, interaction of the ligand with Arg367 of 5-HT7R is shown to differentiate agonists and antagonists. In the pharmacophore model study, two distinct pharmacophore models can tell whether a ligand is an agonist or an antagonist. Taken together, this study provides valuable information for designing novel compounds with selective agonistic or antagonistic properties against 5-HT7R.

Oxidative iodination of deactivated arenes in concentrated sulfuric acid with I2/NaIO4 and KI/NaIO4 iodinating systems

Deactivated arenes were mono- or diiodinated with strong electrophilic I+ reagents, which were prepared from NaIO4 and either I2 or KI in concentrated H2SO4 (minimum 95% by weight). In general a small excess of the dark brown iodinating solution was used (1.1/1.5 equivalents, for nitrobenzene two equivalents was required). The iodinations were conducted at 25-30 °C with a reaction time of 1-2 hours using either a 'direct' or an 'inverse' method of aromatic iodination to give mono- or diiodinated pure products in 31-91% optimized yields. Georg Thieme Verlag Stuttgart.

Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Structure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing KATP openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective KATP channel openers may have utility in the treatment of overactive bladder.

Novel radioligands and their use for identifying potassium channel modulators

The present invention relates to novel radioligands and test methods using those radioligands in screening compounds.

Pyrano, piperidino, and thiopyrano compounds and methods of use

The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.

Potassium channel openers

Compounds having the formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE

Novel diazepine derivatives which selectively inhibit adenosine monophosphate deaminase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine